MDWD Stock Analysis: Buy, Sell, or Hold?
MDWD - MediWound Ltd.
$14.22
0.10 (0.71%)
▲
5d:
-1.59%
30d:
-6.2%
90d:
-14.49%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When MDWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDWD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MDWD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MDWD is currently trading at $14.22, which is considered slightly low relative to its 30-day fair value range of $14.22 to $14.84.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $13.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.17 (+112.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDWD is in a strong downtrend. The price is currently testing key support at $13.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MDWD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.17 (+112.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$14.22 -
$14.84
Company Quality Score
44/100
(HOLD)
Options IV Signal
63th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 63th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.1% below Wall St target ($30.17)
Trading Range Analysis
30-Day Trading Range
$14.22 -
$14.84
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.66
(11.7%)
Support & Resistance Levels
Support Level
$13.91
Resistance Level
$14.87
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.41
Wall Street Target
$30.17
(+112.1%)
Revenue Growth (YoY)
-62.7%
Profit Margin
-180.3%
Share & Embed Analysis
Last updated: August 04, 2026 2:30 AM ET
Data refreshes hourly during market hours. Next update: 3:30 AM
Data refreshes hourly during market hours. Next update: 3:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
